Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031..., Market Research Report: MarketsandMarkets
Дата публикации: 03-07-2026 00:00:00
Основное содержимое страницы с новостью.
Biomarkers Market by Offering (Consumables, Software, Service), Type (Safety, Efficacy, Validation), Research Area (Genomics, Proteomics), Technology (PCR, NGS, MS), Disease (Cancer, CVD), Application (Diagnostic, Drug Discovery) - Global Forecast to 2031
USD 112.10 BN
MARKET SIZE, 2031
BIOMARKERS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global biomarkers market is projected to grow from USD 67.95 billion in 2026 to USD 112.10 billion by 2031, at a CAGR of 10.5% during the forecast period. The market was valued at USD 62.67 billion in 2025. A biomarker (short for biological marker) is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response.
KEY TAKEAWAYS
-
BY REGION
By region, the Asia Pacific biomarkers market is the fastest-growing regional segment, growing at a CAGR of 12.4% during the forecast period.
-
BY OFFERING
By offering, the consumables segment held the largest share of 73.4% in 2025.
-
BY TYPE
By type, the safety biomarkers segment dominates the global biomarkers market in 2025, with a share of 48.5%.
-
BY RESEARCH AREA
By research area, the genomics segment is expected to dominate the market during the forecast period.
-
COMPETITIVE LANDSCAPE - KEY PLAYERS
F. Hoffmann-La Roche (Switzerland), Abbott (US), and Thermo Fisher Scientific (US) were identified as the star players in the global biomarkers market, given their strong market share and product footprint.
-
COMPETITIVE LANDSCAPE - STARTUPS/SMES
DNAnexus, Inc. (US), Biocartis NV (Belgium), and Alamar Biosciences, Inc. (US) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global biomarkers market is expanding rapidly, driven by the surge in precision-medicine programs and the routine use of biomarker-guided tests in oncology, cardiology, and other complex diseases.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The biomarkers market is experiencing rapid growth due to changes in manufacturing and regulatory environments that align with precision medicine and biologic therapies. The increasing demand for diagnoses in cancer, cardiovascular diseases, and neurological conditions is driving the adoption of high-performance assay kits, multiplexing platforms, and single-sample multi-omics solutions that deliver accurate and clinically relevant data. Hospitals, laboratory networks, and contract development and manufacturing organizations (CDMOs) are embracing validated, automation-friendly biomarker consumables and solutions that yield fast results, support companion diagnostics, and comply with strict FDA regulations.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
OPPORTUNITIES
Impact
Level
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The rising adoption of precision medicine and companion diagnostics is driving the demand for biomarker discovery and validation solutions. Advances in genomics, proteomics, metabolomics, and high-throughput screening technologies are improving the efficiency of biomarker identification, enhancing clinical validation capabilities, and supporting greater scalability in both research and clinical applications.
The high costs associated with advanced analytical platforms, multi-omics technologies, clinical validation studies, and regulatory compliance continue to hinder the widespread adoption of biomarkers. Significant investments are needed in infrastructure, skilled expertise, and data integration capabilities, which present challenges, especially for smaller research organizations and emerging biotechnology companies.
The increasing integration of biomarkers with targeted therapies and immunotherapies is creating opportunities for the collaborative development of drugs and diagnostics. There is a growing emphasis on patient stratification, treatment response prediction, and personalized treatment approaches. This focus is driving demand for companion diagnostic solutions and expanding their commercial potential in precision healthcare.
Transforming biomarker discoveries from the research stage into clinically validated diagnostic tests is challenging for several reasons. These include complex validation requirements, regulatory expectations, concerns about reproducibility, and a lack of standardization across clinical settings. To achieve successful commercialization and adoption of these tests, it is essential to ensure analytical accuracy and demonstrate clinical utility.
BIOMARKERS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
NGS-based comprehensive genomic profiling (CGP) and multi-omic biomarkers (including high-sensitive Troponin T, NT-proBNP) for cancer, cardiovascular, and neurology applications. | Supports personalized treatment plans, rapid rule-in/rule-out diagnostics from single tests, earlier detection, and companion diagnostics across oncology, cardiology, and neurology. |
|
|
High-sensitivity immunoassays and blood-based biomarkers for cancer, cardiovascular, and neurological diseases, including amyloid β testing for Alzheimer’s. | Enables non-invasive early diagnosis, risk stratification, and monitoring for chronic conditions like Alzheimer's, cancer, and CVD. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The biomarkers market is a complex ecosystem that includes assay developers, suppliers of kits and instruments, clinical laboratories, hospitals, and biopharmaceutical companies. Biomarker vendors provide validated assays and analytical platforms that pharmaceutical companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs) incorporate into clinical trial designs, patient stratification, and therapeutic response assessments. Hospitals and reference laboratories then integrate these biomarker solutions into clinical practice, with support from healthcare IT vendors, distribution channels, and reimbursement systems that facilitate test adoption, optimize supply chains, and ensure reimbursement. This highly interconnected value chain enables the global implementation of biomarker-based precision medicine strategies within healthcare systems.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
In 2025, consumables accounted for the largest share of the biomarkers market, driven by the steady, high-volume demand for assay kits, reagents, plates, and cartridges in routine clinical diagnostics and extensive research programs.
In 2025, safety biomarkers accounted for the largest share, fueled by their expanding role in real-time tracking of organ toxicity and adverse drug effects across clinical trials and post-approval monitoring.
In 2025, genomics will be a leading research area due to the widespread adoption of next-generation sequencing and gene panels to identify treatment-relevant mutations and develop integrated biomarker profiles for oncology and rare disease initiatives.
In 2025, immunoassay technologies held the largest market share due to their automation-friendly nature and suitability for high-volume routine testing in hospitals and reference laboratories.
In 2025, cancer dominated biomarker spending, as oncology programs rely heavily on molecular and protein markers for early detection, patient stratification, minimal residual disease tracking, and therapy monitoring.
Clinical diagnostics accounted for the largest share of the biomarkers market, as hospitals and reference labs increasingly use biomarker-based tests for routine cancer, cardiovascular, and infectious disease workups.
Pharmaceutical & biotechnology companies formed the largest end-user group by harnessing biomarkers to mitigate R&D risks, design efficient clinical trials, and secure regulatory approval for companion diagnostics tied to novel therapies.
REGION
APAC to be fastest-growing region in market during forecast period
During the forecast period, the Asia Pacific region is expected to experience the fastest growth in the global biomarkers market. This growth is attributed to the expansion of healthcare infrastructure, increased clinical trial activity, and robust government support for precision medicine initiatives, particularly in key countries such as China, India, and Japan.
BIOMARKERS MARKET: COMPANY EVALUATION MATRIX
In the global biomarkers market, F. Hoffmann-La Roche Ltd. (Switzerland) is the star player, offering an extensive portfolio of FDA-cleared and CE-marked assays, automated immunoassay platforms, and integrated diagnostic solutions trusted worldwide for high-throughput testing in oncology, cardiology, neurology, and infectious disease panels. Guardant Health (emerging leader) leverages advanced NGS liquid biopsy tests, comprehensive cancer panels, and AI-driven analytics to transform circulating tumor DNA biomarkers into actionable insights for early detection, therapy selection, and minimal residual disease monitoring across major healthcare systems globally.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 62.47 Billion |
| Market Forecast in 2026 (Value) | USD 67.95 Billion |
| Market Forecast in 2031 (Value) | USD 112.10 Billion |
| Growth Rate | CAGR of 10.5% from 2026–2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends |
| Segments Covered |
|
| Countries Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: BIOMARKERS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Regulatory compliance for global markets | Assessed regulatory requirements for biomarker assays across major markets, including FDA, EMA, and PMDA guidelines. | Reduces time-to-market risk by ensuring assays meet local regulations and compliance standards. |
| Emerging biomarker trends and unmet needs | Identified high-value biomarkers in oncology, immunology, and chronic diseases with limited commercial availability. | Informs pipeline prioritization, partnership opportunities, and innovation roadmaps. |
RECENT DEVELOPMENTS
- June 2026 : Roche's first companion diagnostic to assess PTEN protein in prostate cancer has been approved by the FDA. The VENTANA PTEN assay allows for the identification of patients, leading to more targeted treatment decisions.
- January 2025 : Thermo Fisher Scientific, Inc. has partnered with the UK Biobank Pharma Proteomics Project (UKB-PPP) to support the largest biomarker-focused proteomics study in the world.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
4
MARKET OVERVIEW
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.4.3
UNMET NEEDS & WHITE SPACES
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Covers the key developments, trend analysis, and actionable insights to support strategic planning and positioning.5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN GLOBAL BIOMARKERS INDUSTRY
5.2.4
TRENDS IN HEALTHCARE EXPENDITURE
5.3
SUPPLY CHAIN ANALYSIS
5.5.1
EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
5.6.1
INDICATIVE SELLING PRICE TREND OF ASSAY KITS, BY KEY PLAYER, 2023–2025
5.6.2
INDICATIVE SELLING PRICE OF BIOMARKER CONSUMABLES, BY REGION,
5.7.1
IMPORT SCENARIO (HS CODE 382200)
5.7.2
EXPORT SCENARIO (HS CODE 382200)
5.8
KEY CONFERENCES & EVENTS, 2026–2027
5.9
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.10
INVESTMENT & FUNDING SCENARIO
5.12
IMPACT OF 2025 US TARIFFS ON BIOMARKERS MARKET
5.12.3
PRICE IMPACT ANALYSIS
5.12.4
IMPACT ON COUNTRIES/REGIONS
5.12.5
IMPACT ON END-USE INDUSTRIES
6
STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
6.1
KEY EMERGING TECHNOLOGIES
6.1.2
NEXT-GENERATION SEQUENCING (NGS)
6.1.3
POLYMERASE CHAIN REACTION (PCR)
6.1.4
IN SITU HYBRIDIZATION
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
ADJACENT TECHNOLOGIES
6.3.1
ARTIFICIAL INTELLIGENCE (AI) & MACHINE LEARNING (ML)
6.3.2
SENSORS (WEARABLE DEVICES)
6.4
TECHNOLOGY/PRODUCT ROADMAP
6.7
IMPACT OF AI/GEN AI ON BIOMARKERS MARKET
6.7.1
TOP USE CASES & MARKET POTENTIAL
6.7.2
CASE STUDIES OF AI IMPLEMENTATION IN BIOMARKERS MARKET
6.7.3
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.7.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN BIOMARKERS MARKET
6.8
SUCCESS STORIES & REAL-WORLD APPLICATIONS
7
SUSTAINABILITY & REGULATORY LANDSCAPE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
REGULATORY FRAMEWORK/KEY REGULATIONS
7.2
SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
7.3
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
BIOMARKERS MARKET, BY OFFERING (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
9.2.2
REAGENTS & CHEMICALS
10
BIOMARKERS MARKET, BY TYPE (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
9.3.1
PREDICTIVE BIOMARKERS
9.3.2
SURROGATE BIOMARKERS
9.3.3
PHARMACODYNAMICS BIOMARKERS
9.3.4
PROGNOSTIC BIOMARKERS
10.4
VALIDATION BIOMARKERS
11
BIOMARKERS MARKET, BY RESEARCH AREA (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
11.5
OTHER RESEARCH AREAS
NOTE 1: OTHER RESEARCH AREAS INCLUDE TRANSCRIPTOMICS AND CYTOMETRICS.
12
BIOMARKERS MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
12.2.3
PROTEIN MICROARRAYS
NOTE 2: OTHER TECHNOLOGIES INCLUDE ELECTROPHORESIS AND IMAGING TECHNOLOGIES.
13
BIOMARKERS MARKET, BY DISEASE INDICATION (MARKET SIZE & FORECAST TO 2031 – IN VALUE, USD MILLION)
13.2.5
HEMATOLOGICAL CANCERS
13.3.3
RESPIRATORY INFECTIONS (INCLUDING COVID-19, INFLUENZA, RSV)
13.3.4
OTHER INFECTIOUS DISEASES
13.4
IMMUNOLOGICAL DISORDERS
13.4.1
RHEUMATOID ARTHRITIS
13.4.2
INFLAMMATORY BOWEL DISEASE
13.4.3
OTHER IMMUNOLOGICAL DISORDERS
13.5
NEUROLOGICAL DISORDERS
13.5.1
ALZHEIMER’S DISEASE
13.5.2
PARKINSON’S DISEASE
13.5.3
MULTIPLE SCLEROSIS
13.5.4
OTHER NEUROLOGICAL DISORDERS
13.6
METABOLIC & ENDOCRINE DISORDERS
13.5.3
OTHER METABOLIC & ENDOCRINE DISORDERS
13.7
CARDIOVASCULAR DISORDERS
13.8
OTHER DISEASE INDICATIONS
NOTE 3: OTHER CANCERS INCLUDE LIVER CANCER, PANCREATIC CANCER, OVARIAN CANCER, AND BLADDER CANCER.
NOTE 4: OTHER INFECTIOUS DISEASES INCLUDE TB AND SEPSIS.
NOTE 5: OTHER IMMUNOLOGICAL DISORDERS INCLUDE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND PSORIASIS/PSORIATIC ARTHRITIS.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives at major market players, and industry consultants, to gather and validate critical qualitative and quantitative information and assess the market's growth prospects. The global market size estimated through secondary research was then triangulated with primary research inputs to arrive at the final market size
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the global biomarkers market. The secondary sources used for this study include the American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organisation (CDSCO), Center for Disease Evaluation and Research (CDER), Clinical Laboratory Standards Institute (CLSI), Centers for Disease Control and Prevention (CDC), Clinicaltrials.gov, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), Ministry of Food and Drug Safety (MFDS), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), National Medical Products Administration (NMPA), Organisation for Economic Co-operation and Development (OECD), Personalized Medicine Coalition (PMC), Population Health Research Institute (PHRI), Pharmaceuticals and Medical Devices Agency (PMDA), World Bank, World Health Organization (WHO), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations, among others. These sources were also used to obtain key information on major players, market classification and segmentation aligned with industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Following an initial assessment of the global biomarkers market landscape through secondary research, comprehensive primary research was undertaken. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were conducted with key supply-side participants, including C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% were conducted with demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephone discussions to comprehensively understand market dynamics.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both bottom-up and top-down approaches were used to estimate and validate the total size of the global biomarkers market. These methods were also used extensively to estimate the size of various market subsegments. The research methodology used to estimate the market size includes the following:
- A list of the major global players operating in the biomarkers market was generated.
- The revenues generated from their biomarker products have been determined through annual reports and secondary sources (including paid databases)
- The products were mapped according to the segments of the market. Percentage shares and splits were determined by each segment's revenue. This was verified using secondary sources and by industry experts.
- All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.
Biomarkers Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes.
The biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery & development, personalized medicine, and clinical research. It also examines the adoption of biomarkers across key research areas, including oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type into safety, efficacy, and validation biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarkers landscape.
Key Stakeholders
- Academic & Research Institutes
- Biomarkers Assay & Reagent Manufacturers, Vendors, and Distributors
- Start-ups, platform technology & service providers
- Contract Research Organizations (CROs)
- Diagnostic product providing companies
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensic Labs
- Government organizations
- Private Research Firms
- Contract Development and Manufacturing Organizations (CDMOs)
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the global biomarkers market by offering, type, research area, technology, disease indication, application, end user, and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biomarkers market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global biomarkers market and comprehensively analyze their product & service portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the biomarkers market
- To benchmark players within the biomarkers market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product & service strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations to meet the company’s needs. The following customization options are available for this report:
Portfolio Assesment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.
Regional Analysis
- A further breakdown of the Rest of Asia Pacific biomarkers market into countries
- A further breakdown of the Rest of Europe biomarkers market into countries
- A further breakdown of the Rest of Latin America biomarkers market into countries
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Схожие новости
Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.marketsandmarkets.com.